Aims: To examine the incidence of amputation in patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose co-transporter 2 (SGLT2) inhibitors overall, and canagliflozin specifically, compared with non-SGLT2 inhibitor antihyperglycaemic agents (AHAs).
chronic lower extremity ulceration, including diabetic peripheral neuropathy, vascular insufficiency and infection, all of which can precede a traumatic lower extremity amputation. 5 Additionally, cardiovascular (CV) disease is a well-documented risk factor for amputation in patients with T2DM. 6, 7 Optimal glycaemic control is associated with reduced risk of lower extremity amputation and other microvascular events, and is the cornerstone of diabetes therapy. 8, 9 Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce plasma glucose by increasing the renal threshold for glucose, leading to increased urinary glucose excretion and a mild osmotic diuresis that may be associated with a reduction in intravascular volume. 10, 11 Canagliflozin, dapagliflozin and empagliflozin are SGLT2 inhibitors approved for the treatment of T2DM in the USA. [12] [13] [14] Analysis of data from the CANVAS Program, which comprises 2 large CV outcomes trials of canagliflozin in patients with T2DM and a history or high risk of CV disease, the CANagliflozin cardioVascular Assessment Study (CANVAS) and CANVAS-Renal (CANVAS-R),
showed an increased risk of lower extremity amputation, mainly of the toe and middle of the foot, with canagliflozin. In the CANVAS Program, amputation rates were 6.3 and 3.4 per 1000 person-years with canagliflozin and placebo, respectively. 15 The amputation rates were 5.9 and 2.8 per 1000 person-years with canagliflozin and placebo, respectively, in CANVAS, and 7.5 and 4.2 per 1000 person-years with canagliflozin and placebo, respectively, in CANVAS-R. 16 The US Food and Drug
Administration issued a Drug Safety Communication based on these findings, and the US prescribing information has been modified to reflect an increased risk of amputation in patients with high risk of CV events or a history of CV events. 16, 17 No imbalance in the risk of amputation in patients with high CV risk was reported in the completed EMPA-REG OUTCOME study of empagliflozin, although that trial did not systematically collect adequate data to confirm or refute this risk. 18 The Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) trial, a large-scale CV outcomes trial of dapagliflozin, is ongoing and is now required by the European Medicines Agency to collect data systematically on and report amputation events. 19 Although an amputation imbalance was observed in the CAN-VAS Program, no such imbalance was observed across the canagliflozin phase III and IV study programme, which included more than 8100 patients with T2DM at low CV risk. In the non-CANVAS canagliflozin studies, the incidence rates of amputation were 0. 
| MATERIALS AND METHODS
This was an observational, retrospective, new-user cohort study.
| Data source
Eligible patients were identified using the Truven MarketScan CCAE database, a large administrative health claims database for active employees, early retirees and their dependents, insured by employersponsored plans in the USA. All study variables were based on insurance claims. the observation period were excluded from this study.
| Sample size
The incidence of BKLE amputation was described separately for patients with established CV disease and those without established CV disease (ie, based on baseline CV disease status). Because the CCAE database does not reflect a random sample of a general population, these incidence calculations are direct observations, and CIs are not provided. Established CV disease was defined as any record of a diagnosis (cerebrovascular disease, myocardial infarction or peripheral vascular disease) or a procedure (coronary artery bypass graft, percutaneous coronary intervention or peripheral revascularization) during the baseline period (Table S2 ).
| Cohort follow-up
Patients were followed from the index date until the end of their observation time, regardless of whether they discontinued, switched or augmented treatment (ie, intent-to-treat approach). The primary outcome was the incident case of BKLE amputation, as defined by observing an associated procedure code in the outpatient or inpatient medical service claims between the index date and the end of the observation period.
| Propensity score estimation and matching
We used EPS matching to reduce potential confounding by imbalanced baseline covariates; new users of canagliflozin were matched 1:1 to new users of non-SGLT2 inhibitor AHAs. Large-scale EPS was estimated using regularized logistic regression models, 20 with the dependent variable being canagliflozin new user, and independent variables being the baseline confounders over the 12 months prior to the exposure index date. To avoid over-fitting models and to accommodate a large number of predictors, the regularized logistic regression model was fit using a cyclic coordinate descending method with L 1 penalty (ie, least absolute shrinkage and selection operator). 21 The optimal regularization hyper-parameter was estimated using 10-fold cross-validation. A conventional greedy algorithm with nearestneighbour matching minimizing the absolute difference between EPS was used for matching. 22 The maximum matching caliper of the EPS (on the logit scale) was 20% of the standard deviation of the logit of the EPS. 23 Standardized differences were tabulated across potential confounders to evaluate the matching effectiveness in achieving baseline covariate balance. 24 2.6 | Statistical analyses 2.6.1 | Descriptive summary
Crude incidence rates of BKLE amputation were estimated as the number of first BKLE amputation cases divided by the total at-risk follow-up time, and reported per 1000 person-years at risk, for patients treated with canagliflozin, dapagliflozin, empagliflozin, any SGLT2 inhibitor, and non-SGLT2 inhibitor AHAs, which were further stratified by CV disease status.
| Comparative analysis
A comparative analysis was performed using the conditional Cox proportional hazards model. While formal statistical comparisons were based on EPS-matched cohorts, residual confounding might still be present; therefore, negative controls were used to perform empirical calibration to correct P values generated by the conditional Cox proportional hazards model to further control for random and systematic errors. [25] [26] [27] Both uncalibrated and calibrated P values are presented.
Kaplan-Meier plots were generated for the risk of BKLE amputation over time in the EPS-matched new users of canagliflozin and non-SGLT2 inhibitor AHAs.
| Sensitivity analysis
A sensitivity analysis was performed that compared the risk of ampu- 
| Crude incidence of BKLE amputation
The crude incidence of BKLE amputation in the overall SGLT2
inhibitor population was relatively low (1. 
| Sensitivity analysis
The sensitivity analysis produced results that were consistent with the primary analysis. The cohorts were sufficiently comparable and 
| DISCUSSION
This large, observational, retrospective study was based on real-world patient data in an EPS-matched population with an average age of 53 years, where~8% of patients had peripheral vascular disease, 3.2% had renal impairment, and 1.4% had congestive heart failure. In the present study, we found that the overall risk of incident BKLE amputation was relatively low and found no evidence that the risk differs between patients with T2DM who were new users of canagliflozin and those who were new users of non-SGLT2 inhibitor AHAs.
The findings from this observational study should be interpreted within the context of the total available evidence. As described above, no imbalance in the risk of amputation was observed in the and high CV risk, the incidence of non-traumatic BKLE amputation was increased~2-fold. 15 The observed difference in BKLE amputation risk in these analyses may be attributable to differences in the study populations, specifically with respect to CV risk; more studies are needed to investigate the risk of amputation in patients with high CV risk in a real-world setting. Currently, the mechanism behind the increased risk of BKLE amputation with canagliflozin in patients with T2DM and high CV risk is not well understood, although volume depletion and the potential for reduced tissue perfusion (because of the mechanism of the pharmacological action associated with this class of drug) may have played a role. The present study was strengthened by the use of a large patient database that provided information on real-world experience and is representative of the US commercially insured population. Use of this large, detailed database also allowed balancing of potential confounders by EPS matching. In addition, the use of negative control outcomes enabled us to further assess and minimize the likelihood of unmeasured confounding and systematic error.
As with all observational research, the present study is subject to several potential limitations. In spite of the more than 10 000
baseline variables that were included as potential confounders in were originally constructed for financial reimbursement for services rather than research purposes. As such, some recorded and coded claims data may not be accurate and complete, and could be confounded by financial incentives. Furthermore, it was noted that the rate of amputation in the present study was lower than the rate reported in the CANVAS Program; this may be attributable, in part, to differences in patient age, duration of T2DM and prevalence of CV disease at baseline. Because the database reflects the experience of a commercially insured population, most of the study patients were aged <65 years, which may limit the study's generaliz- 
